Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Feasibility and physiological relevance of designing highly potent aminopeptidase-sparing leukotriene A4 hydrolase inhibitors.

Numao S, Hasler F, Laguerre C, Srinivas H, Wack N, Jäger P, Schmid A, Osmont A, Röthlisberger P, Houguenade J, Bergsdorf C, Dawson J, Carte N, Hofmann A, Markert C, Hardaker L, Billich A, Wolf RM, Penno CA, Bollbuck B, Miltz W, Röhn TA.

Sci Rep. 2017 Oct 19;7(1):13591. doi: 10.1038/s41598-017-13490-1.

2.

Pathophysiological Consequences of a Break in S1P1-Dependent Homeostasis of Vascular Permeability Revealed by S1P1 Competitive Antagonism.

Bigaud M, Dincer Z, Bollbuck B, Dawson J, Beckmann N, Beerli C, Fishli-Cavelti G, Nahler M, Angst D, Janser P, Otto H, Rosner E, Hersperger R, Bruns C, Quancard J.

PLoS One. 2016 Dec 22;11(12):e0168252. doi: 10.1371/journal.pone.0168252. eCollection 2016.

3.

An oral sphingosine 1-phosphate receptor 1 (S1P(1)) antagonist prodrug with efficacy in vivo: discovery, synthesis, and evaluation.

Angst D, Janser P, Quancard J, Buehlmayer P, Berst F, Oberer L, Beerli C, Streiff M, Pally C, Hersperger R, Bruns C, Bassilana F, Bollbuck B.

J Med Chem. 2012 Nov 26;55(22):9722-34. doi: 10.1021/jm3009508. Epub 2012 Oct 26.

PMID:
23067318
4.

A potent and selective S1P(1) antagonist with efficacy in experimental autoimmune encephalomyelitis.

Quancard J, Bollbuck B, Janser P, Angst D, Berst F, Buehlmayer P, Streiff M, Beerli C, Brinkmann V, Guerini D, Smith PA, Seabrook TJ, Traebert M, Seuwen K, Hersperger R, Bruns C, Bassilana F, Bigaud M.

Chem Biol. 2012 Sep 21;19(9):1142-51. doi: 10.1016/j.chembiol.2012.07.016.

5.

Design and preparation of 2-benzamido-pyrimidines as inhibitors of IKK.

Waelchli R, Bollbuck B, Bruns C, Buhl T, Eder J, Feifel R, Hersperger R, Janser P, Revesz L, Zerwes HG, Schlapbach A.

Bioorg Med Chem Lett. 2006 Jan 1;16(1):108-12. Epub 2005 Oct 19.

PMID:
16236504
6.

Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis.

Revesz L, Bollbuck B, Buhl T, Eder J, Esser R, Feifel R, Heng R, Hiestand P, Jachez-Demange B, Loetscher P, Sparrer H, Schlapbach A, Waelchli R.

Bioorg Med Chem Lett. 2005 Dec 1;15(23):5160-4. Epub 2005 Sep 28.

PMID:
16198561
7.

Chemical synthesis and biological properties of pyridine epothilones.

Nicolaou KC, Scarpelli R, Bollbuck B, Werschkun B, Pereira MM, Wartmann M, Altmann KH, Zaharevitz D, Gussio R, Giannakakou P.

Chem Biol. 2000 Aug;7(8):593-9.

8.

Total synthesis of 16-desmethylepothilone B, epothilone B10, epothilone F, and related side chain modified epothilone B analogues.

Nicolaou KC, Hepworth D, King NP, Finlay MR, Scarpelli R, Pereira MM, Bollbuck B, Bigot A, Werschkun B, Winssinger N.

Chemistry. 2000 Aug 4;6(15):2783-800.

PMID:
10985727
9.

A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells.

Giannakakou P, Gussio R, Nogales E, Downing KH, Zaharevitz D, Bollbuck B, Poy G, Sackett D, Nicolaou KC, Fojo T.

Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2904-9.

Supplemental Content

Loading ...
Support Center